Navigation Links
Hepatitis C Phase 2A Trial Positive Results
Date:10/10/2011

SYDNEY, Oct. 10, 2011 /PRNewswire-Asia/ --

  • Phase 2a trial validates Biotron's novel drug
  • First-in-class new, oral drug
  • Good results on tolerability and efficacy
  • Full data to be presented to scientific conference in December

  • Australian drug development company Biotron Limited (ASX:BIT) has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

    Preliminary analysis of trial data confirms that BIT225, an orally administered, small molecule drug, has good antiviral activity against HCV. Patients receiving BIT225 in combination with interferon and ribavirin (the current standard of care for treating HCV) had greater reductions in HCV levels than patients receiving standard of care treatment alone.

    Patients receiving the 400 mg dose of BIT225 showed the greatest levels of virus reduction, with an improvement of ~1 log (a measure of the amount of reduction of the virus in the blood of patients) over standard of care treatment at the completion of the dosing phase with BIT225. This is a significant improvement over and above the standard of care treatment in this patient group.

    Twenty four patients who had passed a stringent screening process were randomly assigned to receive either 400 mg or 200 mg BIT225, or placebo (ratio of 1:1:1), for the first 28 days of their standard treatment with interferon and ribavirin. The trial was undertaken at the Siriraj Hospital, Bangkok, Thailand. All patients were infected with genotype 1 HCV, which is the most common type of HCV and the most resistant to current treatment.

    Since the completion of the clinical phase of dosing with BIT225 in August, samples have been analysed and the resultant data has been subject to preliminary review by the independent D
    '/>"/>

    SOURCE Biotron
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
    2. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
    3. Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
    4. Updated Hepatitis C Practice Guidelines Now Available from AASLD
    5. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
    6. Mainor Eglet Attorney, Robert Eglet, Calls Teva Pharmaceuticals Vice President Craig Lea to the Stand in Hepatitis C Trial
    7. Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
    8. Hepatitis B Vaccine - Comprehensive Patent Search
    9. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    10. FDA approves Incivek for hepatitis C
    11. FDA Approves Victrelis for Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
    (Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
    (Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
    Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
    ... team of,researchers at West Virginia University has shown ... the habits of their adopted country, increasing,their risks ... cancer,among females., "Breast cancer and prostate cancer ... lifestyle play a major role in these cancers,",said ...
    ... Limited (ASX:,CYT) today announced that it is commencing ... company,s novel vascular-disrupting anticancer agent,in patients with an ... (GBM)., The GBM clinical trial is the ... tumor indications for the company and the second ...
    Cached Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3
    (Date:12/24/2014)... Dallas, TX (PRWEB) December 24, 2014 ... has announced the expansion of his practice and med-spa ... to the practice’s growing list of cosmetic treatments and ... a solution into the skin,” says Dr. Ho. “As ... aging changes such as wrinkles, sun spots, discolorations or ...
    (Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier that ... occasion outfits, unveils 65 new bridesmaid dresses ... prices, up to 80% off. , Yunx.co.uk’s dresses are ... designs, gorgeous looks and delicate craftsmanship. These new bridesmaid ... to designing and offering high-quality women’s dresses with fast ...
    (Date:12/24/2014)... (PRWEB) December 25, 2014 BambooIndustry.com a ... for many years. Today, the company announces its ... a special offer on these new products. , Bamboo ... renewable bamboo. The multiple layer bamboo panel board features ... both strong and emissions free. The bamboo panel consists ...
    (Date:12/24/2014)... News) -- Hepatitis C infection does not contribute to mental ... Treatment advances have made it possible for people with ... thinking problems, mood swings and other types of mental impairment ... that long-term infections with other viruses -- a common problem ... of the prime suspects has been the hepatitis C virus, ...
    (Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Researchers say they ... that develop into eggs and sperm. While this ... is the first time that these types of cells ... efficiently using human stem cells, according to the team ... creation of primordial germ cells is one of the ...
    Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2
    ... 20 The following is a statement of ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) The ... Harkin (D-IA) for his leadership role in Senate ... Food and Drug Administration (FDA) regulatory authority over ...
    ... Balance, Inc. (Nasdaq: SMBL ) today held its ... CEO Stephen Hughes spoke to stockholders about the Company,s progress ... year, consumers have found Smart Balance,s brand proposition compelling as ... of spreads," Hughes said. "We are excited as ever ...
    ... Minnesota MINNEAPOLIS, May 20 Today ClearWay Minnesota,s ... to reducing tobacco,s harm through coalition building, public ... resources to communities outside the Twin Cities metro ... to reducing tobacco,s harm and educate all Minnesotans ...
    ... the Archdiocese of Boston may soon refer women ... Centene Corp. and archdiocese-run Caritas Christi Health Care.(Logo: ... over the impact of nationalized health care on ... to ethically compromise with a potential federal health ...
    ... in only one-third of cases, study says , , WEDNESDAY, May ... come to a hospital with the intense chest pain that ... procedures within a few hours, a new Canadian study finds. ... attack and won,t be harmed by waiting a day or ...
    ... highlighted in June 2009 issue of Pregnancy BALTIMORE, May ... "Website We Can,t Live Without" for June 2009.The website ... rest and preterm labor that is current, concise, and ... and reliable, and then gives women a place to ...
    Cached Medicine News:Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 3Health News:ClearWay Minnesota(SM) Board Approves Four Regional Grants 2Health News:ALL: Boston Archdiocese Reportedly on Track for Abortion Referring Venture 2Health News:When Chest Pain Requires Quick Action in ER 2Health News:When Chest Pain Requires Quick Action in ER 3Health News:Pregnancy Magazine Names KeepEmCookin.com its 'Website We Can't Live Without' 2
    30 Degree Angle Shaft with 1.0mm 90 Degree Angle Tip; in stainless steel....
    0.5mm "K" hook. Rounded knurled handle; shaft angled 11mm from tip; overall length 120mm, in Titanium....
    Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm...
    ... Catheter is indicated for balloon ... of a coronary artery or ... purpose of improving myocardial perfusion. ... also designed to provide distal ...
    Medicine Products: